From July 2013 to July 2017, the company allegedly caused medical providers to submit false claims to Medicare for the device, according to a Dec. 11 news release from the Justice Department.
The device, SphenoCath, was intended to treat migraines by administering nerve blocks. The government alleges the device was not approved by the FDA for use in nerve blocks to treat headaches.
The government also alleges Dolor instructed medical providers to submit improper Medicare billing codes.
The company is required to repay the government based on its ability to pay.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.